Dieter J Meyerhoff1, Anderson Mon1, Thomas Metzler2, Thomas C Neylan2. 1. Department of Radiology and Biomedical Imaging, Center for Imaging of Neurodegenerative Diseases, DVA Medical Center, and University of California San Francisco, San Francisco, CA. 2. Psychiatry Research Service VAMC, and University of California San Francisco, San Francisco, CA.
Abstract
STUDY OBJECTIVES: To test if posttraumatic stress disorder (PTSD) is associated with low brain gamma-aminobutyric acid (GABA) levels and if reduced GABA is mediated by poor sleep quality. DESIGN: Laboratory study using in vivo proton magnetic resonance spectroscopy (1H MRS) and behavioral testing. SETTING: VA Medical Center Research Service, Psychiatry and Radiology. PATIENTS OR PARTICIPANTS: Twenty-seven patients with PTSD (PTSD+) and 18 trauma-exposed controls without PTSD (PTSD-), recruited from United States Army reservists, Army National Guard, and mental health clinics. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: 1H MRS at 4 Tesla yielded spectra from three cortical brain regions. In parieto-occipital and temporal cortices, PTSD+ had lower GABA concentrations than PTSD-. As expected, PTSD+ had higher depressive and anxiety symptom scores and a higher Insomnia Severity Index (ISI) score. Higher ISI correlated with lower GABA and higher glutamate levels in parieto-occipital cortex and tended to correlate with lower GABA in the anterior cingulate. The relationship between parieto-occipital GABA and PTSD diagnosis was fully mediated through insomnia severity. Lower N-acetylaspartate and glutamate concentrations in the anterior cingulate cortex correlated with higher arousal scores, whereas depressive and anxiety symptoms did generally not influence metabolite concentrations. CONCLUSIONS: Low brain gamma-aminobutyric acid (GABA) concentration in posttraumatic stress disorder (PTSD) is consistent with most findings in panic and social anxiety disorders. Low GABA associated with poor sleep quality is consistent with the hyperarousal theory of both primary insomnia and PTSD. Our data demonstrate that poor sleep quality mediates low parieto-occipital GABA in PTSD. The findings have implications for PTSD treatment approaches.
STUDY OBJECTIVES: To test if posttraumatic stress disorder (PTSD) is associated with low brain gamma-aminobutyric acid (GABA) levels and if reduced GABA is mediated by poor sleep quality. DESIGN: Laboratory study using in vivo proton magnetic resonance spectroscopy (1H MRS) and behavioral testing. SETTING: VA Medical Center Research Service, Psychiatry and Radiology. PATIENTS OR PARTICIPANTS: Twenty-seven patients with PTSD (PTSD+) and 18 trauma-exposed controls without PTSD (PTSD-), recruited from United States Army reservists, Army National Guard, and mental health clinics. INTERVENTIONS: None. MEASUREMENTS AND RESULTS:1H MRS at 4 Tesla yielded spectra from three cortical brain regions. In parieto-occipital and temporal cortices, PTSD+ had lower GABA concentrations than PTSD-. As expected, PTSD+ had higher depressive and anxiety symptom scores and a higher Insomnia Severity Index (ISI) score. Higher ISI correlated with lower GABA and higher glutamate levels in parieto-occipital cortex and tended to correlate with lower GABA in the anterior cingulate. The relationship between parieto-occipital GABA and PTSD diagnosis was fully mediated through insomnia severity. Lower N-acetylaspartate and glutamate concentrations in the anterior cingulate cortex correlated with higher arousal scores, whereas depressive and anxiety symptoms did generally not influence metabolite concentrations. CONCLUSIONS: Low brain gamma-aminobutyric acid (GABA) concentration in posttraumatic stress disorder (PTSD) is consistent with most findings in panic and social anxiety disorders. Low GABA associated with poor sleep quality is consistent with the hyperarousal theory of both primary insomnia and PTSD. Our data demonstrate that poor sleep quality mediates low parieto-occipital GABA in PTSD. The findings have implications for PTSD treatment approaches.
Authors: Brigitte A Apfel; Jessica Ross; Jennifer Hlavin; Dieter J Meyerhoff; Thomas J Metzler; Charles R Marmar; Michael W Weiner; Norbert Schuff; Thomas C Neylan Journal: Biol Psychiatry Date: 2010-11-20 Impact factor: 13.382
Authors: George Bush; Brent A Vogt; Jennifer Holmes; Anders M Dale; Douglas Greve; Michael A Jenike; Bruce R Rosen Journal: Proc Natl Acad Sci U S A Date: 2001-12-26 Impact factor: 11.205
Authors: Rebecca K Sripada; Anthony P King; Robert C Welsh; Sarah N Garfinkel; Xin Wang; Chandra S Sripada; Israel Liberzon Journal: Psychosom Med Date: 2012-10-31 Impact factor: 4.312
Authors: Ryan E Tyler; Benjamin Z S Weinberg; Dennis F Lovelock; Laura C Ornelas; Joyce Besheer Journal: Genes Brain Behav Date: 2020-08-25 Impact factor: 3.449
Authors: Brian S Mohlenhoff; Linda L Chao; Shannon T Buckley; Michael W Weiner; Thomas C Neylan Journal: Alzheimers Dement Date: 2014-06 Impact factor: 21.566
Authors: Josephine C McGowan; Collin Hill; Alessia Mastrodonato; Christina T LaGamma; Alexander Kitayev; Rebecca A Brachman; Niven R Narain; Michael A Kiebish; Christine A Denny Journal: Neuropsychopharmacology Date: 2018-03-29 Impact factor: 7.853
Authors: Kimberly A Arditte Hall; Sumaiya E DeLane; George M Anderson; Tiffany R Lago; Rachel Shor; Weiwei Wang; Ann M Rasmusson; Suzanne L Pineles Journal: Psychopharmacology (Berl) Date: 2021-02-23 Impact factor: 4.530